Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8140189 | 0.83 | EPAS1 (0.50) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL28227860 | 0.78 | KDM4E (0.46) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL8373115 | 0.78 | MAPT (0.46) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL7812112 | 0.78 | MAPT (0.46) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL291757 | 0.75 | KDM4E (0.40) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL1441635 | 0.75 | MAPT (0.43) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL14359227 | 0.75 | KDM4E (0.43) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL3987910 | 0.75 | MAPT (0.43) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL15758696 | 0.75 | MAPT (0.43) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL30763211 | 0.74 | FAAH (0.44) | KDM4EMAPTALDH1A1HSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | claimed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2007058990-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| WO-2006091862-A2 | CYTOKINE INHIBITORS AND THEIR USE IN THERAPY | KEMIA, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8987271-B2 | 2,2′-biphenazine compounds and methods useful for treating disease | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2655334-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | Eutropics Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012088438-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2007058990-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| CN-1878769-A | Cytokine inhibitors | KEMIA INC (US) | 2006-12-13 | — | — | CN | disclosed |
| WO-2006091862-A2 | CYTOKINE INHIBITORS AND THEIR USE IN THERAPY | KEMIA, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | KDM4E 3490/4885MAPT 3744/4885ALDH1A1 1019/4885 |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | MCL1, BCL3, BCL9 | KDM4E 1427/4885MAPT 3173/4885ALDH1A1 2774/4885 |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | MCL1, BCL3, BCL2L1 | KDM4E 709/4885MAPT 4221/4885ALDH1A1 1106/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | KDM4E 243/4885MAPT 3950/4885ALDH1A1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.